Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | American Journal of Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667723001204 |
| _version_ | 1797672009054814208 |
|---|---|
| author | Mohamad Hekmat Sukkari Basma Al-Bast Raad Al Tamimi William Giesing Momin Siddique |
| author_facet | Mohamad Hekmat Sukkari Basma Al-Bast Raad Al Tamimi William Giesing Momin Siddique |
| author_sort | Mohamad Hekmat Sukkari |
| collection | DOAJ |
| description | Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of ASCVD. Those with elevated lipoprotein (a) [Lp(a)] levels are at increased risk of ASCVD. In this article, we provide an overview of studies that have explored the use of aspirin therapy in individuals with elevated Lp(a). We discuss the potential mechanisms by which aspirin therapy may reduce ASCVD risk, and present a review of the data on the effectiveness of aspirin therapy in reducing ASCVD risk in individuals with elevated Lp(a). The presented evidence suggests that individuals with elevated Lp(a) benefit more from aspirin therapy for reduction of ASCVD events than the general population. |
| first_indexed | 2024-03-11T21:23:50Z |
| format | Article |
| id | doaj.art-5c1a8780939042ae99568fccb1f272e9 |
| institution | Directory Open Access Journal |
| issn | 2666-6677 |
| language | English |
| last_indexed | 2024-03-11T21:23:50Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Preventive Cardiology |
| spelling | doaj.art-5c1a8780939042ae99568fccb1f272e92023-09-28T05:26:37ZengElsevierAmerican Journal of Preventive Cardiology2666-66772023-09-0115100579Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidenceMohamad Hekmat Sukkari0Basma Al-Bast1Raad Al Tamimi2William Giesing3Momin Siddique4Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL, USA; Corresponding author at: 751N Rutledge St Rm 1100, Springfield, IL 62702, USA.Cardiovascular Division, Southern Illinois University School of Medicine, Springfield, IL, USAInternal Medicine, Southern Illinois University School of Medicine, Springfield, IL, USAMethodist Dallas Medical Center, Internal medicine, Dalles, TX, USACardiovascular Division, Southern Illinois University School of Medicine, Springfield, IL, USAAspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of ASCVD. Those with elevated lipoprotein (a) [Lp(a)] levels are at increased risk of ASCVD. In this article, we provide an overview of studies that have explored the use of aspirin therapy in individuals with elevated Lp(a). We discuss the potential mechanisms by which aspirin therapy may reduce ASCVD risk, and present a review of the data on the effectiveness of aspirin therapy in reducing ASCVD risk in individuals with elevated Lp(a). The presented evidence suggests that individuals with elevated Lp(a) benefit more from aspirin therapy for reduction of ASCVD events than the general population.http://www.sciencedirect.com/science/article/pii/S2666667723001204Lipoprotein aCoronary artery diseaseAspirinHyperlipidemiaCardiovascular riskAtherosclerotic cardiovascular disease |
| spellingShingle | Mohamad Hekmat Sukkari Basma Al-Bast Raad Al Tamimi William Giesing Momin Siddique Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence American Journal of Preventive Cardiology Lipoprotein a Coronary artery disease Aspirin Hyperlipidemia Cardiovascular risk Atherosclerotic cardiovascular disease |
| title | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
| title_full | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
| title_fullStr | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
| title_full_unstemmed | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
| title_short | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
| title_sort | is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated lipoprotein a a review of the evidence |
| topic | Lipoprotein a Coronary artery disease Aspirin Hyperlipidemia Cardiovascular risk Atherosclerotic cardiovascular disease |
| url | http://www.sciencedirect.com/science/article/pii/S2666667723001204 |
| work_keys_str_mv | AT mohamadhekmatsukkari isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT basmaalbast isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT raadaltamimi isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT williamgiesing isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT mominsiddique isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence |